Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Nivolumab

Placeholder slot
 (nih-VOL-yoo-mab)

Nivolumab keeps cancer cells from suppressing the immune system by binding to and blocking the protein PD-1 on the surface of some cancer cells. This allows the immune system to attack the cancer cells. Nivolumab is a type of immunotherapy drug called an immune checkpoint inhibitor.

US Brand Name(s)
Opdivo
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Nivolumab is approved to treat:

  • classic Hodgkin lymphoma. Nivolumab is used:
  • colorectal cancer in adults and children aged 12 years and older whose cancer is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Nivolumab is used:
  • esophageal cancer. Nivolumab is used in adults:
    • for certain esophageal cancers that have been treated with chemoradiation and then surgery to completely remove the cancer, but cancer cells were found in the removed tissue
    • for squamous cell carcinoma of the esophagus that cannot be removed by surgery or has spread or come back after treatment with a fluoropyrimidine and platinum chemotherapy
    • for squamous cell carcinoma of the esophagus that has the PD-L1 protein and cannot be removed by surgery or has spread to other parts of the body. It is given with either ipilimumab or a fluoropyrimidine and platinum chemotherapy as the first treatment.
  • gastric (stomach) cancer, gastroesophageal junction adenocarcinoma, or esophageal cancer that has the PD-L1 protein and has spread. Nivolumab is used with a fluoropyrimidine and platinum chemotherapy.
  • hepatocellular carcinoma (a type of liver cancer) in adults whose cancer cannot be removed by surgery or has spread to other parts of the body. Nivolumab is used with ipilimumab as the first treatment or after treatment with sorafenib.
  • malignant pleural mesothelioma. Nivolumab is used with ipilimumab as the first treatment in adults whose cancer cannot be removed by surgery.
  • melanoma. Nivolumab is used:
    • alone or with ipilimumab in adults and children aged 12 years and older whose cancer cannot be removed by surgery or has spread to other parts of the body
    • to keep the cancer from coming back after surgery that completely removed the cancer in adults and children aged 12 years and older with one of the following stages of melanoma: stage IIB, IIC, IIIA, IIIB, IIIC, IIID, or IV
  • non-small cell lung cancer in adults. Nivolumab is used:
    • with platinum chemotherapy before surgery for early-stage cancer to keep the cancer from coming back
    • with platinum chemotherapy before surgery for cancer that does not have an abnormal EGFR or ALK gene. It is also given alone after surgery to keep the cancer from coming back.
    • as the first treatment with ipilimumab for cancer that has spread to other parts of the body and has the PD-L1 protein but does not have an abnormal EGFR or ALK gene
    • as the first treatment with ipilimumab and platinum chemotherapy for cancer that has come back or spread to other parts of the body and does not have an abnormal EGFR or ALK gene
    • for cancer that has spread to other parts of the body and has gotten worse during or after treatment with platinum chemotherapy. Patients whose cancer has an abnormal EGFR or ALK gene should receive nivolumab only if their cancer got worse after treatment with FDA-approved therapy for these gene mutations.
  • renal cell carcinoma (a type of kidney cancer) that is advanced. Nivolumab is used in adults:
  • squamous cell carcinoma of the head and neck in adults whose cancer has either spread to other parts of the body or has come back or worsened during or after treatment with platinum chemotherapy
  • urothelial carcinoma (a type of cancer in the bladder or urinary tract) in adults. Nivolumab is used:
    • with cisplatin and gemcitabine as the first treatment for cancer that cannot be removed by surgery or has spread to other parts of the body
    • after surgery to remove cancer that has a high risk of coming back
    • for cancer that has spread and got worse after treatment with platinum chemotherapy

Nivolumab is given by infusion. It is available in a different form, combined with hyaluronidase, that is given subcutaneously. For more information, see the Drug Information Summary for Nivolumab and Hyaluronidase-nvhy. Nivolumab is also available as a combination formulation with a drug called relatlimab. For more information, see the Drug Information Summary for Nivolumab and Relatlimab-rmbw.

Nivolumab is also being studied in the treatment of other types of cancer.

More About Nivolumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Nivolumab - A lay language summary of important information about this drug.

Research Results and Related Resources

FDA Approval Likely to Change Initial Treatment for Some People with Advanced Colorectal Cancer

Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma

Trial Establishes Preferred Treatment for Some People with Esophageal Cancer

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

A Better Biomarker for Cancer Immunotherapy?

Targeted Therapy to Treat Cancer

Monoclonal Antibodies

Immune Checkpoint Inhibitors

Clinical Trials Accepting Patients

Find Clinical Trials for Nivolumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email